Medpace Holdings (MEDP) Cash & Equivalents (2014 - 2026)

Medpace Holdings (MEDP) has reported Cash & Equivalents for 13 consecutive years, with $652.7 million the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $652.7 million, up 47.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $652.7 million (up 47.85% YoY), and the FY2025 annual result was $497.0 million, down 25.75% from the prior year.
• Cash & Equivalents was $652.7 million for Q1 2026 at Medpace Holdings, up from $497.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $669.4 million in Q4 2024 and troughed at $28.3 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $281.1 million, with a median of $245.4 million recorded in 2023.
• Year-over-year, Cash & Equivalents plunged 93.87% in 2022 and soared 1205.37% in 2024.
• Over 5 years, Cash & Equivalents stood at $28.3 million in 2022, then jumped by 768.38% to $245.4 million in 2023, then jumped by 172.74% to $669.4 million in 2024, then retreated by 25.75% to $497.0 million in 2025, then soared by 31.31% to $652.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $652.7 million in Q1 2026, $497.0 million in Q4 2025, and $285.4 million in Q3 2025.